Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:422697rdf:typepubmed:Citationlld:pubmed
pubmed-article:422697lifeskim:mentionsumls-concept:C0030705lld:lifeskim
pubmed-article:422697lifeskim:mentionsumls-concept:C0003009lld:lifeskim
pubmed-article:422697lifeskim:mentionsumls-concept:C0001206lld:lifeskim
pubmed-article:422697lifeskim:mentionsumls-concept:C0005823lld:lifeskim
pubmed-article:422697lifeskim:mentionsumls-concept:C1704632lld:lifeskim
pubmed-article:422697lifeskim:mentionsumls-concept:C0871261lld:lifeskim
pubmed-article:422697lifeskim:mentionsumls-concept:C2911692lld:lifeskim
pubmed-article:422697lifeskim:mentionsumls-concept:C1706817lld:lifeskim
pubmed-article:422697lifeskim:mentionsumls-concept:C0231491lld:lifeskim
pubmed-article:422697pubmed:issue1lld:pubmed
pubmed-article:422697pubmed:dateCreated1979-5-23lld:pubmed
pubmed-article:422697pubmed:abstractTextThe renin-angiotensin-aldosterone system in patients with acromegaly was evaluated by infusing [sarcosine1, isoleucine8]angiotensin II, a competitive angiotensin II antagonist, into five acromegalic patients with hypertension and three normotensive acromegalics. The drug was infused at a rate of 600 ng/kg . min for 30 min, 1 h after iv injection of 40 mg furosemide. In addition, before the infusion, plasma samples were obtained for determination of PRA and plasma aldosterone concentration. A significant pressor response to [sarcosine1, isoleucine8]angiotensin II was observed in all eight patients. Preinfusion PRA and plasma aldosterone concentration were significantly lower than in normal controls. It is concluded that in acromegaly, the renin-angiotensin-aldosterone system is suppressed and that this system is probably not involved in maintenance of the high blood pressure observed in some acromegalic patients.lld:pubmed
pubmed-article:422697pubmed:languageenglld:pubmed
pubmed-article:422697pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:422697pubmed:citationSubsetAIMlld:pubmed
pubmed-article:422697pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:422697pubmed:statusMEDLINElld:pubmed
pubmed-article:422697pubmed:monthJanlld:pubmed
pubmed-article:422697pubmed:issn0021-972Xlld:pubmed
pubmed-article:422697pubmed:authorpubmed-author:OkadaYYlld:pubmed
pubmed-article:422697pubmed:authorpubmed-author:HataTTlld:pubmed
pubmed-article:422697pubmed:authorpubmed-author:MikamiHHlld:pubmed
pubmed-article:422697pubmed:authorpubmed-author:KumaharaYYlld:pubmed
pubmed-article:422697pubmed:authorpubmed-author:OgiharaTTlld:pubmed
pubmed-article:422697pubmed:authorpubmed-author:MaruyamaAAlld:pubmed
pubmed-article:422697pubmed:authorpubmed-author:NakamaruMMlld:pubmed
pubmed-article:422697pubmed:issnTypePrintlld:pubmed
pubmed-article:422697pubmed:volume48lld:pubmed
pubmed-article:422697pubmed:ownerNLMlld:pubmed
pubmed-article:422697pubmed:authorsCompleteYlld:pubmed
pubmed-article:422697pubmed:pagination159-62lld:pubmed
pubmed-article:422697pubmed:dateRevised2004-11-17lld:pubmed
pubmed-article:422697pubmed:meshHeadingpubmed-meshheading:422697-H...lld:pubmed
pubmed-article:422697pubmed:meshHeadingpubmed-meshheading:422697-H...lld:pubmed
pubmed-article:422697pubmed:meshHeadingpubmed-meshheading:422697-A...lld:pubmed
pubmed-article:422697pubmed:meshHeadingpubmed-meshheading:422697-B...lld:pubmed
pubmed-article:422697pubmed:meshHeadingpubmed-meshheading:422697-F...lld:pubmed
pubmed-article:422697pubmed:meshHeadingpubmed-meshheading:422697-M...lld:pubmed
pubmed-article:422697pubmed:meshHeadingpubmed-meshheading:422697-A...lld:pubmed
pubmed-article:422697pubmed:meshHeadingpubmed-meshheading:422697-M...lld:pubmed
pubmed-article:422697pubmed:meshHeadingpubmed-meshheading:422697-A...lld:pubmed
pubmed-article:422697pubmed:year1979lld:pubmed
pubmed-article:422697pubmed:articleTitleBlood pressure response to an angiotensin II antagonist in patients with acromegaly.lld:pubmed
pubmed-article:422697pubmed:publicationTypeJournal Articlelld:pubmed